Loading...
•
Jun 30, 2020
Gilead Sciences Q2 2020 Earnings Report
Gilead Sciences announced results for the second quarter of 2020, with product sales of $5.1 billion and a GAAP loss of $(2.66) per share.
Key Takeaways
Gilead Sciences reported second-quarter revenue of $5.1 billion. GAAP net loss was $(3.3) billion, or $(2.66) per share, which included an acquired in-process research and development (“IPR&D”) charge of $4.5 billion related to Gilead’s acquisition of Forty Seven, Inc. Non-GAAP diluted EPS was $1.11 per share.
Second Quarter Product Sales of $5.1 billion
First Half Product Sales of $10.5 billion
Second Quarter GAAP Loss of $(2.66) per share
Second Quarter Non-GAAP Diluted EPS of $1.11 per share
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Gilead revised its full year 2020 guidance, initially provided on February 4, 2020.
Positive Outlook
- Product Sales of $23 billion to $25 billion
- Non-GAAP Product Gross Margin 86% - 87%
- R&D Expenses Mid-teens percentage growth
- SG&A Expenses High-single digit percentage growth
- Operating Income of $10.7 billion - $13.0 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...